Carbapenem-resistant Enterobacteriaceae (CRE)

The Enterobacteriaceae include a large family of Gram-negative bacilli found in the human gastrointestinal tract. Commonly encountered species include Escherichia coli, Klebsiella spp. and Enterobacter spp. Carbapenem-resistant Enterobacteriaceae (CRE) are not susceptible to carbapenem antibiotics. They are broadly categorized based on the mechanism of their resistance as carbapenemase producers (CP-CRE) and non-carbapenemase producers.

Carbapenems are broad-spectrum antibiotics typically used to treat severe health care-associated infections (HAIs) caused by highly drug-resistant bacteria. Currently available carbapenems include imipenem, meropenem, ertapenem and doripenem. Although related to the β-lactam antibiotics, carbapenems retain antibacterial activity in the presence of most β-lactamasases, including extended-spectrum β-lactamasases (ESBLs) and extended-spectrum cephalosporinases (e.g., AmpC-type β-lactamasases). Loss of susceptibility to carbapenems is a serious problem because few safe treatment alternatives remain against such resistant bacteria.

Infections caused by CRE occur most commonly among people with chronic medical conditions through use of invasive medical devices such as central venous and urinary catheters, frequent or prolonged stays in health care settings or extended courses of antibiotics. CP-CRE are most concerning and have spread rapidly across the nation and around the globe, perhaps because carbapenemases can be encoded on plasmids that are easily transferred within and among bacterial species.

In December 2011, CRE bacterial isolates became reportable in Oregon. The CRE case definition has gone through major changes over the years, which is reflected in the big changes in case numbers from year to year. In 2013, the definition was non-susceptible (intermediate or resistant) to all carbapenems tested and resistant to any third generation cephalosporins tested. The definition was then revised in 2014 to non-susceptible to any carbapenem, excluding ertapenem, and resistant to all third generation cephalosporins tested. A CDC study found this definition to be too insensitive in picking up carbapenemase producers. The current definition, which changed July 1, 2015, is Enterobacteriaceae with resistance to any carbapenem antibiotic. This definition is simpler and aligned with the CDC’s definition.

The Oregon State Public Health Laboratory offers specialized testing to determine whether reported CRE are carbapenemase producers, and the Oregon Public Health Division’s HAI program performs detailed investigation of any reported cases.
One-hundred twenty-two cases of CRE infection or colonization were reported among Oregon residents in 2017. Ninety-six (79%) of cases were ≥60 years old, median age was 73, and 74 (61%) were female. Urine was the most common source (76%) and Enterobacter cloacae accounted for 52% of all isolates.

By the end of 2017, Oregon had 17 CP-CRE in Oregon residents; 11 Klebsiella pneumoniae carbapenemase (KPC), four New Delhi metallo-ß-lactamase (NDM) and two oxacillinase-48 (OXA-48). Thirteen (76%) of the CP-CRE were from patients with histories of health care exposure in other states or out of the United States.

Unlike much of the rest of the country, we have no indication CP-CRE are spreading in Oregon. We have instituted enhanced surveillance and prevention efforts and established the Drug-Resistant Organism Prevention and Coordinated Regional Epidemiology (DROP-CRE) Network, a statewide network to rapidly detect, respond to and prevent CRE.

For more information, including our CRE toolkit, please see Carbapenem-resistant Enterobacteriaceae.
Incidence of carbapenem-resistant *Enterobacteriaceae* by age and sex: Oregon, 2017

Carbapenem-resistant *Enterobacteriaceae* by species: Oregon, 2017

- **60%** *Enterobacter*
- **14%** *Klebsiella*
- **12%** *E. coli*
- **2%** *Citrobacter*
- **2%** *Other*
- **10%** *Serratia*
Incidence of carbapenem-resistant *Enterobacteriaceae* by county of residence: Oregon, 2012–2017

Prevention

- Think “**NICE**” if you encounter CRE:
  - **Notify** the county health department, pertinent clinical groups and your antibiotic stewardship program that CRE has been spotted.
  - **Intervene** in all cases with core infection control activities: hand hygiene, contact precautions, private rooms and optimized environmental cleaning. Reduce unnecessary antibiotics and use of invasive devices. Additionally, for CP-CRE, screen patient contacts as well as cohort staff and patients.
  - **Communicate** CRE infection or colonization status to the receiving facility upon patient transfer.
  - **Educate** patients, staff and visitors about CRE.